Furthermore, despite many studies depicting the relevance of immune checkpoints expressed on circulating EVs in the context of cancer (immuno)therapy [42, 43], to our knowledge no study has yet demonstrated the role of EV-bound CD27 as a predictive biomarker in patients undergoing ICI, and, more importantly, how this acts antagonistically to soluble CD27. Here, CD27 is linked to cancer.